Asset sale Pending Sponsor buyer
Nuvo Pharmaceuticals (Ireland) DAC acquisition of Cumberland FDA-approved commercial products and related assets
US$100m consideration
Announced 22 Apr 2026
Advisers
Cumberland FDA-approved commercial products and related assets
Target
- Financial adviser
- Legal adviser
- Baker Donelson (as Baker, Donelson, Bearman, Caldwell & Berkowitz, P.C.)
- Fairness opinion
- Target
- Cumberland FDA-approved commercial products and related assets
- Acquirer
- Nuvo Pharmaceuticals (Ireland) DAC
- Sponsor
- Apotex
- Seller
- Cumberland Pharmaceuticals
- Target based in
- United States
- Buyer based in
- Ireland
- Seller based in
- United States
- Sector
- Pharma
In the league tables
Similar deals
- Shionogi & Co. acquisition of Shionogi-Apnimed Sleep Science Apr 2026 · US$100m · Pharma
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
- Tarsus Pharmaceuticals acquisition of iRenix Medical Jul 2026 · US$75m · Ophthalmology
- Esperion Therapeutics acquisition of Corstasis Therapeutics Mar 2026 · US$75m · Pharma
- SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA May 2026 · US$134m · Pharma
Sources
- 26 May 2026 Definitive merger proxy statement (DEFM14A), CUMBERLAND PHARMACEUTICALS INC sec.gov
